Roganovic J. Late effects of the treatment of childhood cancer. World J Clin Cases 2025; 13(7): 98000 [DOI: 10.12998/wjcc.v13.i7.98000]
Corresponding Author of This Article
Jelena Roganovic, MD, PhD, Adjunct Professor, Department of Pediatric Oncology and Hematology, Children's Hospital Zagreb, Klaiceva 16, Zagreb 10000, Croatia. jelena.roganovic02@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Mar 6, 2025; 13(7): 98000 Published online Mar 6, 2025. doi: 10.12998/wjcc.v13.i7.98000
Late effects of the treatment of childhood cancer
Jelena Roganovic
Jelena Roganovic, Department of Pediatric Oncology and Hematology, Children's Hospital Zagreb, Zagreb 10000, Croatia
Jelena Roganovic, Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka 51000, Croatia
Author contributions: Roganovic J designed and wrote entire original draft; the author read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The author declares no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jelena Roganovic, MD, PhD, Adjunct Professor, Department of Pediatric Oncology and Hematology, Children's Hospital Zagreb, Klaiceva 16, Zagreb 10000, Croatia. jelena.roganovic02@gmail.com
Received: June 14, 2024 Revised: October 22, 2024 Accepted: November 14, 2024 Published online: March 6, 2025 Processing time: 163 Days and 17.9 Hours
Core Tip
Core Tip: Childhood cancer and contemporary anticancer therapies responsible for excellent cure rates can produce adverse, long-term, health-related outcomes, referred to as late effects. Therapy-related long-term complications may affect multiple organs and organ systems, including cardiovascular, endocrine/metabolic, reproductive, neurologic, immune, pulmonary, gastrointestinal, urinary, musculoskeletal, auditory, ocular, dermatologic and oral/dental organs, as well as contribute to the risk of neurocognitive and psychosocial difficulties, and subsequent malignant neoplasms. Many of these late effects are life-altering or potentially life-threatening. Long-term multidisciplinary follow-up of childhood cancer survivors is recommended for the prevention, early detection, and treatment of late effects.
